CPT code 48100 represents an open surgical pancreatic biopsy where a surgeon obtains a tissue sample from a pancreatic lesion and sends it for pathologic evaluation. This code captures a discrete operative procedure distinct from less invasive sampling techniques and is relevant for surgical, oncologic, and diagnostic care pathways. Nationally, accurate coding of pancreatic biopsy procedures affects case mix, reimbursement, and clinical documentation tied to cancer diagnosis and management.

Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The report addresses coverage considerations and typical billing patterns across major commercial insurers and the federal program.

Readers will find a concise clinical and coding overview, expected sites of service and service type, typical modifiers and payer considerations where available, and guidance on how the code fits into surgical and pathology workflows. The publication also summarizes common documentation elements that support use of the code, outlines related clinical contexts for which the procedure is performed, and notes when additional services or global period rules may apply. Data not available in the input is indicated explicitly.